/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Valued at a market cap of $21.2 billion, Moderna, Inc. (MRNA) is a biotechnology company that pioneered the use of messenger RNA (mRNA) therapeutics and vaccines to transform how medicines are created. The Cambridge, Massachusetts-based company is expected to announce its fiscal Q1 earnings for 2026 before the market opens on Friday, May 1.
Ahead of this event, analysts expect this biotechnology company to report a loss of $2.27 per share, down 9.9% from a loss of $2.52 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. In Q4 2025, Moderna’s loss of $2.11 per share outpaced the consensus expectations by a notable margin of 18.9%.